Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03672877
Other study ID # Pro00080569
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 28, 2019
Est. completion date December 31, 2025

Study information

Verified date May 2024
Source University of Alberta
Contact Donna Livingstone, BScPT
Phone 780-492-4858
Email carre@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled trial, comparing 3 months of intensive leg exercise to standard physiotherapy care for the improvement of gross motor function in young children with spastic diplegia.


Description:

Children born prematurely are at risk of brain injury that can result in cerebral palsy, most often affecting both legs. Current treatment is largely passive, including leg braces, repeated injection of a paralyzing agent (botulinum toxin) in muscles that are abnormally active, and surgery as deformities occur. Active, physical therapy for weak muscles is infrequent, occurring twice a month or less. Yet, recent work in mammals show that early brain injury can be alleviated by intensive exercise therapy, but only while the animal is very young. Building on our success with early, intensive therapy for children with perinatal stroke, we will apply intensive therapy for the legs in children with cerebral palsy involving both legs. Children (8 mo - 3 yr old) will be randomly assigned to start treatment immediately or delay treatment for 6 months. The delay period controls for improvement without treatment. The children in the Delay Group will have the option to receive the same treatment after the delay period. The therapy will be guided by physical therapists, and centered on play. Measures will be taken before, during and after the delay and treatment periods. Measures will include clinical scores of motor development, proficiency of walking, participation at home, and physiological measures of motor and sensory function. All children will be followed until they turn 4 yr old, to determine if there are long term benefits. The cost-effectiveness of the intervention will be evaluated by a health economist. We anticipate that early intensive exercise will improve mobility, facilitate earlier and better walking, and that the effects will be enduring.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Months to 36 Months
Eligibility Inclusion Criteria: - Bilateral motor impairment of the lower extremities - Periventricular white matter injury from encephalopathy of prematurity - Able to stand with some support Exclusion Criteria: - Substantial upper extremity involvement - Manual Abilities Classification System (MACS) Level =3 - Uncontrolled epilepsy or infantile spasms in the past 6 months - Cardiovascular or musculoskeletal complications that preclude participation in intensive exercise - Botulinum toxin-A (BTX-A) injections in the legs in the last 6 months

Study Design


Intervention

Behavioral:
Intensive exercise
Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.

Locations

Country Name City State
Canada Alberta Children's Hospital Calgary Alberta
Canada University of Alberta Edmonton Alberta

Sponsors (2)

Lead Sponsor Collaborator
University of Alberta Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Gross Motor Functional Measure - 66 Items (GMFM-66) This is a 66 item criterion-referenced observational measure to assess change in gross motor function of children with cerebral palsy. From Baseline to 6 months
Secondary Change on Pediatric Quality of Life Measure module for cerebral palsy (PedsQL CP) A questionnaire format completed by parents including 5 scales: 1) daily activities, 2) movement and balance, 3) pain and hurt, 4) fatigue, and 5) eating activities. From Baseline to 6 months
Secondary Change in stiffness at the ankle The portable spasticity assessment device (PSAD) will be used to measure response to stretch in the ankle plantarflexors. A hand-held segment of the device is applied to a limb segment to measure the forces applied by the hand to the limb and the motion of the limb. Disposable, surface electromyographic electrodes are applied to the skin of the limb to measure the muscle activity. From Baseline to 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Completed NCT00375908 - Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury N/A
Active, not recruiting NCT00515281 - Inhaled Nitric Oxide and Neuroprotection in Premature Infants Phase 2/Phase 3
Completed NCT03635775 - Single-session tDCS in Cerebral Palsy N/A
Completed NCT02342990 - Telerehabilitation of Working Memory in Children With Periventricular Leukomalacia and Bilateral Cerebral Palsy N/A
Active, not recruiting NCT04873752 - A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy Phase 1/Phase 2
Terminated NCT00589953 - High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study Phase 2
Completed NCT00120588 - Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Phase 4
Completed NCT04077333 - MISA to NRDS:a Multicenter Study in China N/A
Terminated NCT00303082 - Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity Phase 3
Completed NCT00413946 - Does Erythropoietin Improve Outcome in Very Preterm Infants? Phase 2
Completed NCT02784821 - Antibiotic "Dysbiosis" in Preterm Infants Phase 2
Completed NCT04535375 - Sonographic QUantification of Venous Circulation In the Preterm Brain N/A
Completed NCT00014989 - Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Phase 3
Withdrawn NCT03527498 - Evaluation of Long-term Neurodevelopment in Neonatal Encephalopathy by Infant Treadmill N/A
Terminated NCT03534466 - Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill N/A
Recruiting NCT05520359 - Spinal Stimulation and Mobility Devices N/A
Completed NCT02221219 - Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury Phase 1/Phase 2
Recruiting NCT02814383 - Prediction of Brain Injury in Premature Infants
Recruiting NCT03110341 - Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome Phase 3